T-E Meds supported YmmunoBio in the development of an MMAF/Exatecan dual-payload ADC, which was recently incorporated into a novel ADC study targeting NPTXR. The findings from this research have been published in an international peer-reviewed journal. The study developed a novel dual-payload ADC combining MMAF and Exatecan, two payloads with distinct mechanisms of action, and […]

T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital structure. The company is also actively pursuing international partnership opportunities, with the goal of listing on the Taiwan Emerging Stock

We are honored to announce that Dr. Tse-Wen Chang, Chairman of T-E Pharma, and Dr. Hsin-Mao Chu, CEO of the T-E Pharma, have been invited to participate in BIOLOGICS WORLD TAIWAN 2026, to be held in Taiwan, where they will deliver keynote presentations. BIOLOGICS WORLD TAIWAN is Taiwan’s premier annual biotherapeutics industry event, organized by

T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with

Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma. After achieving remarkable